AU2001284995B2 - Slo2 and Slo4, novel potassium channel proteins from human brain - Google Patents

Slo2 and Slo4, novel potassium channel proteins from human brain Download PDF

Info

Publication number
AU2001284995B2
AU2001284995B2 AU2001284995A AU2001284995A AU2001284995B2 AU 2001284995 B2 AU2001284995 B2 AU 2001284995B2 AU 2001284995 A AU2001284995 A AU 2001284995A AU 2001284995 A AU2001284995 A AU 2001284995A AU 2001284995 B2 AU2001284995 B2 AU 2001284995B2
Authority
AU
Australia
Prior art keywords
slo4
slo2
polypeptide
nucleic acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001284995A
Other languages
English (en)
Other versions
AU2001284995A1 (en
Inventor
Timothy James Jegla
Julie Dickson Witzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icagen Inc
Original Assignee
Icagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icagen Inc filed Critical Icagen Inc
Publication of AU2001284995A1 publication Critical patent/AU2001284995A1/en
Application granted granted Critical
Publication of AU2001284995B2 publication Critical patent/AU2001284995B2/en
Priority to AU2007202750A priority Critical patent/AU2007202750A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2001284995A 2000-11-15 2001-08-15 Slo2 and Slo4, novel potassium channel proteins from human brain Ceased AU2001284995B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007202750A AU2007202750A1 (en) 2000-11-15 2007-06-14 SL02 and SL04, novel potassium channel proteins from human brain

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24911200P 2000-11-15 2000-11-15
US60/249,112 2000-11-15
US09/921,159 2001-08-01
US09/921,159 US7041494B2 (en) 2000-11-15 2001-08-01 DNA encoding Slo2 and Slo4, potassium channel
PCT/US2001/025701 WO2002040649A1 (en) 2000-11-15 2001-08-15 Slo2 and slo4, novel potassium channel proteins from human brain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007202750A Division AU2007202750A1 (en) 2000-11-15 2007-06-14 SL02 and SL04, novel potassium channel proteins from human brain

Publications (2)

Publication Number Publication Date
AU2001284995A1 AU2001284995A1 (en) 2002-08-01
AU2001284995B2 true AU2001284995B2 (en) 2007-03-29

Family

ID=26939832

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001284995A Ceased AU2001284995B2 (en) 2000-11-15 2001-08-15 Slo2 and Slo4, novel potassium channel proteins from human brain
AU8499501A Pending AU8499501A (en) 2000-11-15 2001-08-15 Slo2 and slo4, novel potassium channel proteins from human brain

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU8499501A Pending AU8499501A (en) 2000-11-15 2001-08-15 Slo2 and slo4, novel potassium channel proteins from human brain

Country Status (7)

Country Link
US (4) US7041494B2 (enExample)
EP (2) EP2295454A1 (enExample)
JP (1) JP2005507633A (enExample)
AT (1) ATE525396T1 (enExample)
AU (2) AU2001284995B2 (enExample)
CA (1) CA2428350A1 (enExample)
WO (1) WO2002040649A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003095644A1 (fr) * 2002-05-14 2003-11-20 Takeda Pharmaceutical Company Limited Nouvelles proteines et adn pour lesdites proteines
JP2024505710A (ja) * 2021-02-08 2024-02-07 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 胆汁酸塩バクトセンサー並びに診断及び治療目的のその使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020754A1 (en) * 1997-10-22 1999-04-29 The Washington University A ph sensitive potassium channel in spermatocytes
US20030143676A1 (en) * 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972187B2 (en) * 2000-05-12 2005-12-06 Millennium Pharmaceuticals, Inc. OAT5 molecules and uses therefor
US20040009474A1 (en) * 2000-05-24 2004-01-15 Leach Martin D. Novel human polynucleotides and polypeptides encoded thereby
US20020048787A1 (en) * 2000-06-14 2002-04-25 Ming-Hui Wei Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
US20040224911A1 (en) * 2000-08-03 2004-11-11 Henry Yue Transporters and ion channels
WO2003000842A2 (en) * 2001-06-04 2003-01-03 Curagen Corporation Novel proteins and nucleic acids encoding same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020754A1 (en) * 1997-10-22 1999-04-29 The Washington University A ph sensitive potassium channel in spermatocytes
US20030143676A1 (en) * 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Joiner et al. 1998. Nature Neuroscience. 1: 462-469 *
Nagase, T. et al. 2000. DNA Research. 7: 65-73 *
Sequence with EMBL Database accession number AB037843 *
Sequence with EMBL Database accession number AW615027 *

Also Published As

Publication number Publication date
US7767450B2 (en) 2010-08-03
WO2002040649A8 (en) 2002-11-07
WO2002040649A1 (en) 2002-05-23
EP1334178A1 (en) 2003-08-13
JP2005507633A (ja) 2005-03-24
US20100267930A1 (en) 2010-10-21
US7411043B2 (en) 2008-08-12
US7041494B2 (en) 2006-05-09
EP2295454A1 (en) 2011-03-16
US20060099640A1 (en) 2006-05-11
US7893209B2 (en) 2011-02-22
CA2428350A1 (en) 2002-05-23
US20030017533A1 (en) 2003-01-23
US20090017534A1 (en) 2009-01-15
EP1334178B1 (en) 2011-09-21
ATE525396T1 (de) 2011-10-15
EP1334178A4 (en) 2006-03-29
AU8499501A (en) 2002-05-27

Similar Documents

Publication Publication Date Title
US7514208B2 (en) Methods for identifying modulators of cyclic nucleotide-gated cation channels
AU780103B2 (en) Kv10.1, a novel voltage-gated potassium channel from human brain
CA2408847C (en) Cng3b: a novel cyclic nucleotide-gated cation channel
AU781111B2 (en) Potassium channel KCNQ5
US7893209B2 (en) Slo2, novel potassium channel proteins from human brain
AU771483B2 (en) Human Eag2
AU2001263183A1 (en) Cng3b: a novel cyclic nucleotide-gated cation channel
AU2001284995A1 (en) Slo2 and Slo4, novel potassium channel proteins from human brain
AU2007202750A1 (en) SL02 and SL04, novel potassium channel proteins from human brain

Legal Events

Date Code Title Description
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY THE ACCEPTANCE FEE HAS BEEN EXTENDED TO 29 JUL 2007.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired